| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6065533 | Journal of Allergy and Clinical Immunology | 2015 | 10 Pages |
Abstract
The risk of major malformations was similar with a LABA plus ICS combination and ICS monotherapy at higher doses, suggesting that both therapeutic options can be considered during pregnancy.
Keywords
MED-ÉCHOAdministrative health databasesRAMQSABAICD-10ICD-9ICSAsthmaLong-acting β2-agonistShort-acting β2-agonistPregnancyCombination therapyLABAInternational Classification of Diseases, Tenth RevisionInternational Classification of Diseases, Ninth RevisionCohort studyCongenital malformationsodds ratioInhaled corticosteroid
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sherif MSc, Amelie MSc, Marie-France PharmD, Lucie PhD,